Effect of guibi-tang, a traditional herbal formula, on retinal neovascularization in a mouse model of proliferative retinopathy

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 29900-29910

  Lee, Yun Mi ^a   Lee, Yu Ri ^a   Kim, Chan Sik ^a   Jo, Kyuhyung ^a   Sohn, Eunjin ^a   Kim, Jin ^a   Kim, Junghyun ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Fibroblast growth factor 2; Oxygen induced retinopathy; Plasminogen activator inhibitor 1; Retinal neovascularization; Vascular endothelial growth factor

Indexed keywords

COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR; GUIBI TANG; MESSENGER RNA; PLANT MEDICINAL PRODUCT; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR 2; GUIBI-TANG; HERBACEOUS AGENT; OXYGEN; VASCULOTROPIN A;

ANGIOGENESIS ASSAY; ARTICLE; FLUORESCENCE MICROSCOPY; HYPEROXIA; MOUSE; NONHUMAN; PROLIFERATIVE RETINOPATHY; PROTEIN EXPRESSION; PROTEIN MICROARRAY; QUANTITATIVE ASSAY; RETINA NEOVASCULARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SEQUENCE ANALYSIS; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RETINA; RETINAL NEOVASCULARIZATION; VITREORETINOPATHY, PROLIFERATIVE;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUGS, CHINESE HERBAL; FIBROBLAST GROWTH FACTOR 2; MICE, INBRED C57BL; OXYGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; REAL-TIME POLYMERASE CHAIN REACTION; RETINA; RETINAL NEOVASCULARIZATION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84949979803     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226211     Document Type: Article

References (62)

1. Patz, A. Studies on retinal neovascularization. Friedenwald Lecture. Investig. Ophthalmol. Vis. Sci. 1980, 19, 1133-1138.
2. Damico, F. M. Angiogenesis and retinal diseases. Arq. Bras. Oftalmol. 2007, 70, 547-553. [CrossRef] [PubMed]
3. Sennlaub, F.; Chemtob, S. VEGFR-1: A safe target for prophylaxis of retinopathy of prematurity? Pediatr. Res. 2004, 55, 1-2. [CrossRef] [PubMed]
4. Smith, L. E.; Kopchick, J. J.; Chen, W.; Knapp, J.; Kinose, F.; Daley, D.; Foley, E.; Smith, R. G.; Schaeffer, J. M. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276, 1706-1709. [CrossRef] [PubMed]
5. Asahara, T.; Bauters, C.; Zheng, L. P.; Takeshita, S.; Bunting, S.; Ferrara, N.; Symes, J. F.; Isner, J. M. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92, 365-371. [CrossRef]
6. Pepper, M. S.; Ferrara, N.; Orci, L.; Montesano, R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 1992, 189, 824-831. [CrossRef]
7. Goto, F.; Goto, K.; Weindel, K.; Folkman, J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab. Investig. 1993, 69, 508-517. [PubMed]
8. Hu, D. E.; Fan, T. P. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A. Br. J. Pharmacol. 1995, 114, 262-268. [CrossRef] [PubMed]
9. D'Amore, P. A. Mechanisms of retinal and choroidal neovascularization. Investig. Ophthalmol. Vis. Sci. 1994, 35, 3974-3979.
10. Pepper, M. S.; Ferrara, N.; Orci, L.; Montesano, R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 1991, 181, 902-906. [CrossRef]
11. Fotsis, T.; Pepper, M.; Adlercreutz, H.; Fleischmann, G.; Hase, T.; Montesano, R.; Schweigerer, L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad. Sci. USA 1993, 90, 2690-2694. [CrossRef] [PubMed]
12. Gils, A.; Declerck, P. J. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb. Haemost. 2004, 91, 425-437. [CrossRef] [PubMed]
13. Tashiro, Y.; Nishida, C.; Sato-Kusubata, K.; Ohki-Koizumi, M.; Ishihara, M.; Sato, A.; Gritli, I.; Komiyama, H.; Sato, Y.; Dan, T.; et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood 2012, 119, 6382-6393. [CrossRef] [PubMed]
14. Basu, A.; Menicucci, G.; Maestas, J.; Das, A.; McGuire, P. Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy. Investig. Ophthalmol. Vis. Sci. 2009, 50, 4974-4981. [CrossRef] [PubMed]
15. Hur, J. Donguibogam; Namsandang: Seoul, Korea, 2007; p. 98.
16. Busta, I.; Xie, H.; Kim, M. S. The use of Gui-Pi-Tang in small animals with immune-mediated blood disorders. J. Vet. Clin. 2009, 26, 181-184.
17. Eun, J. S.; Song, J. M. Effects of Kwibi-tang on serum levels of hormone and the non-specific immune response after immobilization stress in mice. Korean J. Orient. Med. Physiol. Pathol. 2004, 18, 172-178.
18. Lim, J. W.; Kim, J. W.; Chung, S. Y.; Cho, S. H.; Oh, M. S.; Hwang, W. W. The Antioxidative and neuroprotective effect of guibi-tang(Guipitang) and guibi-tang gamibang(guipitang jiaweijang) on PC12!cells. J. Orient. Neuropsychiatry 2009, 20, 1-19.
19. Kim, H. J.; Choi, J. H.; Lim, S. W. The Defensive Effect of Keuibi-tang on the Gastric Mucous Membrane of Mouse Injured by Stress and Ethanol. J. Korean Orient. Med. 2003, 24, 155-168.
20. Rosenfarb, A. Healing Your Eyes with Chinese Medicine: Acupuncture, Acupressure, & Chinese Herbs; North Atlantic Books: Berkeley, CA, USA, 2007.
21. Kim, J. H.; Lee, Y. M.; Ahn, E. M.; Kim, K. W.; Yu, Y. S. Decursin inhibits retinal neovascularization via suppression of VEGFR-2 activation. Mol. Vis. 2009, 15, 1868-1875. [PubMed]
22. Lee, Y. M.; Kim, C. S.; Sohn, E.; Jo, K.; Lim, H. R.; Kim, S. K.; Kim, J. S.; Kim, J. Sipjeondaebo-tang, a traditional herbal formula, inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy. Tohoku. J. Exp. Med. 2014, 234, 229-236. [CrossRef] [PubMed]
23. Stahl, A.; Connor, K. M.; Sapieha, P.; Chen, J.; Dennison, R. J.; Krah, N. M.; Seaward, M. R.; Willett, K. L.; Aderman, C. M.; Guerin, K. I.; et al. The mouse retina as an angiogenesis model. Investig. Ophthalmol. Vis. Sci. 2010, 51, 2813-2826. [CrossRef] [PubMed]
24. Stahl, A.; Connor, K. M.; Sapieha, P.; Willett, K. L.; Krah, N. M.; Dennison, R. J.; Chen, J.; Guerin, K. I.; Smith, L. E. Computer-aided quantification of retinal neovascularization. Angiogenesis 2009, 12, 297-301. [CrossRef] [PubMed]
25. Brower, V. Antiangiogenesis research is booming, as questions and studies proliferate. J. Natl. Cancer Inst. 2009, 101, 780-781. [CrossRef] [PubMed]
26. Choi, H. J.; Armaiz Pena, G. N.; Pradeep, S.; Cho, M. S.; Coleman, R. L.; Sood, A. K. Anti-vascular therapies in ovarian cancer: Moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2014, 34, 19-40. [CrossRef] [PubMed]
27. Casanovas, O.; Hicklin, D. J.; Bergers, G.; Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8, 299-309. [CrossRef] [PubMed]
28. Brower, V. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. J. Natl. Cancer Inst. 2009, 101, 846-847. [CrossRef] [PubMed]
29. Sulaiman, R. S.; Basavarajappa, H. D.; Corson, T. W. Natural product inhibitors of ocular angiogenesis. Exp. Eye Res. 2014, 129, 161-171. [CrossRef] [PubMed]
30. Lee, H. J.; Lee, E. O.; Rhee, Y. H.; Ahn, K. S.; Li, G. X.; Jiang, C.; Lu, J.; Kim, S. H. An oriental herbal cocktail, ka-mi-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis and metastasis. Carcinogenesis 2006, 27, 2455-2463. [CrossRef] [PubMed]
31. Redington, A. E.; Roche, W. R.; Madden, J.; Frew, A. J.; Djukanovic, R.; Holgate, S. T.; Howarth, P. H. Basic fibroblast growth factor in asthma: measurement in bronchoalveolar lavage fluid basally and following allergen challenge. J. Allergy Clin. Immunol. 2001, 107, 384-387. [CrossRef] [PubMed]
32. Yamashita, A.; Yonemitsu, Y.; Okano, S.; Nakagawa, K.; Nakashima, Y.; Irisa, T.; Iwamoto, Y.; Nagai, Y.; Hasegawa, M.; Sueishi, K. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J. Immunol. 2002, 168, 450-457. [CrossRef] [PubMed]
33. Chung, S. W.; Bae, S. M.; Lee, M.; Al-Hilal, T. A.; Lee, C. K.; Kim, J. K.; Kim, I. S.; Kim, S. Y.; Byun, Y. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways. Biomaterials 2015, 37, 271-278. [CrossRef] [PubMed]
34. Cross, M. J.; Claesson-Welsh, L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 2001, 22, 201-207. [CrossRef]
35. Mandriota, S. J.; Pepper, M. S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell Sci. 1997, 110, 2293-2302. [PubMed]
36. Brodsky, S.; Chen, J.; Lee, A.; Akassoglou, K.; Norman, J.; Goligorsky, M. S. Plasmin-dependent and-independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 2001, 281, H1784-H1792. [PubMed]
37. Kwaan, H. C.; Wang, J.; Svoboda, K.; Declerck, P. J. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br. J. Cancer 2000, 82, 1702-1708. [PubMed]
38. Gutierrez, L. S.; Schulman, A.; Brito-Robinson, T.; Noria, F.; Ploplis, V. A.; Castellino, F. J. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 2000, 60, 5839-5847. [PubMed]
39. Bajou, K.; Noel, A.; Gerard, R. D.; Masson, V.; Brunner, N.; Holst-Hansen, C.; Skobe, M.; Fusenig, N. E.; Carmeliet, P.; Collen, D.; et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 1998, 4, 923-928. [CrossRef] [PubMed]
40. Campochiaro, P. A. Ocular neovascularization. J. Mol. Med. 2013, 91, 311-321. [CrossRef] [PubMed]
41. Ambati, J.; Anand, A.; Fernandez, S.; Sakurai, E.; Lynn, B. C.; Kuziel, W. A.; Rollins, B. J.; Ambati, B. K. An animal model of age-related macular degeneration in senescent Ccl-2-or Ccr-2-deficient mice. Nat. Med. 2003, 9, 1390-1397. [CrossRef] [PubMed]
42. Ehlken, C.; Grundel, B.; Michels, D.; Junker, B.; Stahl, A.; Schlunck, G.; Hansen, L. L.; Feltgen, N.; Martin, G.; Agostini, H. T.; et al. Increased expression of angiogenic and inflammatory proteins in the vitreous of patients with ischemic central retinal vein occlusion. PLoS ONE 2015, 10, e0126859. [CrossRef] [PubMed]
43. Lofqvist, C.; Willett, K. L.; Aspegren, O.; Smith, A. C.; Aderman, C. M.; Connor, K. M.; Chen, J.; Hellstrom, A.; Smith, L. E. Quantification and localization of the IGF/insulin system expression in retinal blood vessels and neurons during oxygen-induced retinopathy in mice. Investig. Ophthalmol. Vis. Sci. 2009, 50, 1831-1837. [CrossRef] [PubMed]
44. Li, S. Y.; Fu, Z. J.; Lo, A. C. Hypoxia-induced oxidative stress in ischemic retinopathy. Oxid. Med. Cell. Longev. 2012, 2012, 426769. [CrossRef] [PubMed]
45. Natoli, R.; Valter, K.; Barbosa, M.; Dahlstrom, J.; Rutar, M.; Kent, A.; Provis, J. 670nm photobiomodulation as a novel protection against retinopathy of prematurity: evidence from oxygen induced retinopathy models. PLoS ONE 2013, 8, e72135. [CrossRef] [PubMed]
46. Bodrova, M. E.; Brailovskaya, I. V.; Efron, G. I.; Starkov, A. A.; Mokhova, E. N. Cyclosporin A-sensitive decrease in the transmembrane potential across the inner membrane of liver mitochondria induced by low concentrations of fatty acids and Ca2+. Biochemistry 2003, 68, 391-398. [PubMed]
47. Greco, T.; Shafer, J.; Fiskum, G. Sulforaphane inhibits mitochondrial permeability transition and oxidative stress. Free Radic. Biol. Med. 2011, 51, 2164-2171. [CrossRef] [PubMed]
48. Panfoli, I.; Ravera, S.; Bruschi, M.; Candiano, G.; Morelli, A. Proteomics unravels the exportability of mitochondrial respiratory chains. Expert Rev. Proteom. 2011, 8, 231-239. [CrossRef] [PubMed]
49. Yamamoto, K.; Shimizu, N.; Obi, S.; Kumagaya, S.; Taketani, Y.; Kamiya, A.; Ando, J. Involvement of cell surface ATP synthase in flow-induced ATP release by vascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, 1646-1653. [CrossRef] [PubMed]
50. Moser, T. L.; Stack, M. S.; Asplin, I.; Enghild, J. J.; Hojrup, P.; Everitt, L.; Hubchak, S.; Schnaper, H. W.; Pizzo, S. V. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA 1999, 96, 2811-2816. [CrossRef] [PubMed]
51. Calzia, D.; Oneto, M.; Caicci, F.; Bianchini, P.; Ravera, S.; Bartolucci, M.; Diaspro, A.; Degan, P.; Manni, L.; Traverso, C. E.; et al. Effect of polyphenolic phytochemicals on ectopic oxidative phosphorylation in rod outer segments of bovine retina. Br. J. Pharmacol. 2015, 172, 3890-3903. [CrossRef] [PubMed]
52. Seo, C. S.; Kim, J. H.; Shin, H. K. Simultaneous determination of liquiritin, nodakenin and glycyrrhizinin Guibi-tang, a traditional herbal prescription by HPLC-PDA. Pak. J. Pharm. Sci. 2014, 27, 819-824. [PubMed]
53. Liang, C.; Lee, K. J.; Jeong, S. W.; Ha, J. H.; Ma, J. Y. Analysis of Constituents from Guibi-Tang with Lactobacillus. Int. J. Biosci. Biochem. Bioinform. 2012, 2, 374-376. [CrossRef]
54. Kim, K. J.; Choi, J. S.; Kim, K. W.; Jeong, J. W. The anti-angiogenic activities of glycyrrhizic acid in tumor progression. Phytother. Res. 2013, 27, 841-846. [CrossRef] [PubMed]
55. Lee, Y. M.; Kim, J.; Jo, K.; Shin, S. D.; Kim, C. S.; Sohn, E. J.; Kim, S. G.; Kim, J. S. Ethyl pyruvate inhibits retinal pathogenic neovascularization by downregulating HMGB1 expression. J. Diabetes Res. 2013, 2013, 245271. [CrossRef] [PubMed]
56. Jung, M. H.; Lee, S. H.; Ahn, E. M.; Lee, Y. M. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 2009, 30, 655-661. [CrossRef] [PubMed]
57. Son, S. H.; Kim, M. J.; Chung, W. Y.; Son, J. A.; Kim, Y. S.; Kim, Y. C.; Kang, S. S.; Lee, S. K.; Park, K. K. Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase. Cancer Lett. 2009, 280, 86-92. [CrossRef] [PubMed]
58. Bucolo, C.; Ward, K. W.; Mazzon, E.; Cuzzocrea, S.; Drago, F. Protective effects of a coumarin derivative in diabetic rats. Investig. Ophthalmol. Vis. Sci. 2009, 50, 3846-3852. [CrossRef] [PubMed]
59. Johnson, J.; Maher, P.; Hanneken, A. The flavonoid, eriodictyol, induces long-term protection in ARPE-19 cells through its effects on Nrf2 activation and phase 2 gene expression. Investig. Ophthalmol. Vis. Sci. 2009, 50, 2398-2406. [CrossRef] [PubMed]
60. Bucolo, C.; Leggio, G. M.; Drago, F.; Salomone, S. Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Biochem. Pharmacol. 2012, 84, 88-92. [CrossRef] [PubMed]
61. Kim, M. H. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J. Cell. Biochem. 2003, 89, 529-538. [CrossRef] [PubMed]
62. Cao, P.; Cai, X.; Lu, W.; Zhou, F.; Huo, J. Growth inhibition and induction of apoptosis in SHG-44 glioma cells by Chinese medicine formula "Pingliu Keli". Evid. Based Complement. Alternat. Med. 2011. [CrossRef] [PubMed]